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Extending the clinical and 
mutational spectrum of 
TRIM32-related myopathies in 
a non-Hutterite population
IntroductIon
TRIM32-related myopathies represent a 
phenotypic spectrum of a rare autosomal 
recessive muscle disorder. The disease 
is described as a mild and progressive 
myopathy without characteristic clinical 
features. Originally classified as limb-
girdle muscular dystrophy (LGMD) 2H 
(OMIM #254110), the disorder was first 
identified in the Hutterite population 
and the homozygous TRIM32 founder 
mutation, p.Asp487Asn, was identified 
as the cause of this disease.1 Only seven 
patients with definite non-Hutterite 
TRIM32-related myopathy have been 
reported in the literature. Apart from two 
missense mutations residing in the NHL 
repeats of TRIM32, only deletions, frame-
shift and nonsense mutations have been 
reported.2 Having applied next genera-
tion sequencing technologies to over 1000 
patients with suspected genetic muscle 
disorders, we present nine patients with 
TRIM32-related myopathies and three 
patients with a homozygous TRIM32 
variant of unknown significance (VUS).
SubjectS and methodS
DNA samples from 1000 patients with 
unexplained limb-girdle muscle weak-
ness and/or elevated serum creatine 
kinase (CK) levels were gathered through 
the MYO-SEQ project. Samples were 
processed and whole exome sequencing 
(WES) performed as described previously.3 
Additional patients with TRIM32-re-
lated myopathy were diagnosed by the 
Northern Molecular Genetics Service 
(NMGS) diagnostic laboratory through 
panel sequencing of 32 LGMD genes. 
Variants were classified according to 
ACMG guidelines.4 MRI imaging was 
performed for eight patients on a 1.5T 
MRI platform. Muscle biopsies for all 
patients were analysed following standard 
histological techniques.
reSultS
Genetic findings
Of the 1000 MYO-SEQ patients, we identi-
fied 36 with rare coding variants in TRIM32 
(minor allele frequency <1%; numbered 
1–36 in online supplementary table 1). 
Twenty-six patients had single heterozy-
gous variants; these were discarded from 
our analysis as the variants were unlikely 
to be pathogenic in this autosomal recessive 
disease. Two further patients were excluded 
from our analysis: patient 18 was hetero-
zygous for a pathogenic DES mutation and 
patient 10 was homozygous for a pathogenic 
CAPN3 mutation. This resulted in seven 
patients with suspected pathogenic TRIM32 
variants and one patient with a homozygous 
VUS. We included four additional patients 
harbouring homozygous rare TRIM32 
variants: three from NMGS and one for 
whom WES was performed in Tehran. Two 
patients harboured a pathogenic variant 
and two had a VUS. Pathogenic variants 
outside the NHL repeats were frameshift 
mutations (online supplementary figure 1); 
missense mutations in the coiled-coil region 
and intervening region were classified as a 
VUS.4 
clinical phenotypes
The clinical findings of patients with 
pathogenic TRIM32 variants are described 
in the upper panel of online supplemen-
tary table 2. The main presenting symp-
toms were related to proximal lower limb 
weakness. Axial, facial and periscapular 
muscles were variably involved. Serum 
CK levels were moderately increased 
(≤2000 U/L). Forced vital capacity was 
normal in the eight patients for whom 
we had reliable spirometry. There were 
no patients with a cardiomyopathy. A 
few striking clinical features were noted 
for the patients carrying a homozygous 
TRIM32 VUS (lower panel of online 
supplementary table 2), including marked 
distal upper limb weakness for patient 
16 and childhood onset and high CK for 
patient 38.
muscle imaging
MRI scans of the patients with pathogenic 
TRIM32 variants revealed a preferential 
affection of the posterior thigh compart-
ment, evolving to a diffuse involvement of 
the anterior thigh in later stages (figure 1). 
A consistent involvement of the posterior 
lower leg compartment and the tibialis 
anterior muscle was observed as well as 
the peronei muscles in later stages. There 
was a relative sparing of the flexor hallucis 
longus, flexor digitorum longus and tibi-
alis posterior muscles. MRI images for the 
patients carrying a homozygous VUS did 
not reveal any consistent pattern (online 
supplementary figure 2).
histological features
Muscle biopsies showed non-specific 
myopathic or dystrophic changes. Vacuoles 
containing basophilic material were noted 
in scattered muscle fibres of patients 14, 
15 and 39 (online supplementary figure 3). 
No specific histopathological features were 
noted on the biopsies of patients carrying a 
homozygous VUS in TRIM32.
dIScuSSIon
To our knowledge, other studies have 
never yielded such a large cohort of 
patients with non-Hutterite TRIM32-re-
lated myopathy  and thus we present an 
extended understanding of this rare neuro-
muscular disorder. The highly conserved 
NHL domain was the focal region of the 
pathogenic missense variants in this study, 
with pathogenic variants outside the NHL 
repeats being frameshift variants. A caveat to 
WES is that it is commonly considered to be 
intractable to copy number variation (CNV) 
and repeat expansion detection. However, 
specialised analytical software now permits 
such analysis. Indeed, a heterozygous 63.5 
kb deletion overlapping with p.Arg613Ter 
was identified in patient 36’s exome using a 
modified version of PennCNV on a custom 
Illumina Infinium Array.5 Repeat expansion 
disorders—including facioscapulohumeral 
dystrophy, myotonic dystrophy type 1 and 
2 and oculopharyngeal muscular dystro-
phy—were excluded in case of clinical 
suspicion.
The phenotypes of the patients 
harbouring novel variants were not strik-
ingly different from those of the patients 
with known pathogenic variants. Consis-
tent with the current literature, distal 
upper limb weakness seems to be excep-
tional while axial, facial and periscapular 
muscles were variably involved. Despite 
TRIM32-related myopathy being described 
as a ‘mild’ myopathy, four patients in our 
cohort were wheelchair-dependent. Our 
data do not provide evidence in favour of 
cardiac or respiratory involvement. MRI 
imaging revealed a consistent pattern of 
muscle involvement. The histological 
features in our patients encompassed the 
LGMD2H and ‘sarcotubular myopathy’ 
spectrum that has been described in the 
literature: non-specific myopathic changes 
or dystrophic features sometimes accom-
panied by vacuoles.2
Additionally, we describe the pheno-
types of three patients harbouring a 
homozygous missense TRIM32 VUS. 
For these patients, no other candidate 
variants in known myopathy genes were 
identified. Despite some phenotypic 
characteristics contrasting with those 
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of the patients with definite pathogenic 
variants, we cannot exclude that these 
variants are causal in the disease; future 
functional data will provide insight into 
their pathogenicity.
Overall, we report nine patients 
with TRIM32-related myopathy 
harbouring 10 pathogenic TRIM32 vari-
ants and introduce three patients with 
a homozygous TRIM32 VUS. Comple-
mented with deep phenotyping, our 
application of WES enabled patients with 
TRIM32-related myopathy to be identi-
fied. We propose that similar approaches 
of targeted sequencing and thorough 
curation of phenotypic information will 
expedite future TRIM32-related myop-
athy diagnoses.
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Figure 1  t1-weighted axial MrI of the lower limbs of five patients identified with pathogenic 
TRIM32 variants. MrI images at mid-thigh level on the left and mid-calf level on the right for: (A) 
patient 14 at approximately 14 years of disease duration; (B) patient 15 at 18 years of disease 
duration; (C) patient 27 at 8 years of disease duration; (D) patient 28 at 28 years of disease 
duration; (e) patient 37 at 5 years disease duration. (A–C and e) MrI images at thigh level, with 
slight differences in the exact level of acquisition of the image, revealed a preferential involvement 
of posterior compartment muscles. (D) end-stage involvement of all thigh muscles was observed for 
patient 28. (A–e) MrI images at calf level revealed a similar pattern for all patients, with predominant 
involvement of the posterior compartment. White arrows indicate relatively spared muscles. FDL, flexor 
digitorum longus; FHL, flexor hallucis longus; tP, tibialis posterior.
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